Tempus AI Receives FDA Clearance For Updated Tempus Pixel

2025-09-11 13:17:00 英文原文

作者：September 11, 2025 — 09:17 am EDT

(RTTNews) - Tempus AI, Inc. (TEM) has received 510(k) clearance from the FDA for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device's capabilities for cardiac MR image analysis.

Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus, said: "With inline maps generated by Tempus Pixel, cardiologists and radiologists gain a comprehensive view of heart tissue, enabling deeper insights into cardiac health and helping them deliver more precise, personalized care to their patients."

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

关于《Tempus AI Receives FDA Clearance For Updated Tempus Pixel》的评论

暂无评论

发表评论

摘要

Tempus AI, Inc. (TEM) has received FDA 510(k) clearance for an updated version of its Tempus Pixel platform, which now includes the capability to generate T1 and T2 inline maps, enhancing cardiac MR image analysis. Chris Scotto DiVetta, Senior Vice President at Tempus, highlighted that this update provides cardiologists and radiologists with a more comprehensive view of heart tissue, aiding in delivering precise and personalized patient care.

Tempus AI Receives FDA Clearance For Updated Tempus Pixel

关于《Tempus AI Receives FDA Clearance For Updated Tempus Pixel》的评论

发表评论

摘要

相关新闻

相关讨论